MTVA.US MetaVia Inc.

Healthcare Biotechnology USA Stocks
1.30 USD
Close of Nov 15, 2026
0.9660 13.42
Market cap
USD 8.56M
P/E
-
P/B
1.26x
ROE
-761.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is MTVA.US undervalued?

Graham number

The Graham number of MetaVia Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MetaVia Inc. fundamental analysis

No fundamental analysis for MetaVia Inc. yet.

MetaVia Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MetaVia Inc.

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; …

Full company profile